Clinical Trial Update: Rabbit Anti-thymocyte Globulin in the Treatment of Patients With Low to Intermediate-1 Risk Myelodysplastic Syndrome [Phase 2]

View source ↗

Summary

Phase 2 study of rabbit anti-thymocyte globulin for low- to intermediate-1 risk myelodysplastic syndromes was terminated; results were posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Thymoglobulin (rabbit anti-thymocyte globulin)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Myelodysplastic Syndrome (MDS) | Phase 2 | Status: TERMINATED | Results posted: 2010-04-27